Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (NASDAQ: EQ) announced the acceptance of three abstracts for presentation at the Transplantation & Cellular Meetings from February 2-6, 2022. The abstracts focus on the safety and efficacy of itolizumab in treating acute graft-versus-host disease (aGVHD), highlighting promising outcomes in severe cases. Key findings include a novel targeted therapy's rapid effects on T-cell activity and its role in regulating T effector cell migration. The research underscores the importance of itolizumab for patients with high-risk aGVHD, with no approved first-line treatments currently available.
Equillium, Inc. (Nasdaq: EQ) announced that its CEO, Bruce Steel, will present at the H.C. Wainwright Virtual BioConnect Conference on January 10, 2022, at 7:00 am EST. The presentation will cover key topics, including itolizumab’s mechanism of action and topline data from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD). Regulatory feedback relevant to a pivotal aGVHD study and the EQUALISE study in systemic lupus erythematosus will also be discussed. A webcast will be available on the company’s website for 90 days.
Equillium announced promising findings from a study published in the Journal of Clinical Investigation that highlights the role of the CD6-ALCAM pathway in lupus nephritis (LN). The research included over 1,000 patients and suggests that soluble ALCAM could serve as a biomarker for LN activity. The data supports the development of itolizumab, a monoclonal antibody targeting this pathway, which is currently being evaluated in the EQUALISE clinical study. Encouraging results show itolizumab's potential to reduce disease activity in SLE patients with renal involvement.
Equillium, Inc. (NASDAQ: EQ) announced the successful completion of the Phase 1b EQUIP study of itolizumab, aimed at treating uncontrolled asthma. The study met its primary objective of safety and tolerability, showing that itolizumab effectively reduced cell surface CD6 levels at Day 85 post-treatment. Adverse events were mostly mild to moderate, with transient lymphopenia in 79% of subjects. Although asthma control improved, the small sample size limited significant observations. Equillium plans to focus on pivotal studies for acute graft-versus-host disease and lupus nephritis.
Equillium, Inc. (Nasdaq: EQ) reports promising results from the EQUATE Phase 1b study in acute graft-versus-host disease (aGVHD), with 79% of responders maintaining complete response at six months. The study demonstrated a significant reduction in corticosteroid use among patients. The ongoing EQUATE study aims to establish itolizumab as a first-line treatment for high-risk aGVHD patients. Presentations at the 63rd Annual Meeting of ASH highlighted the drug's durability and safety profile, encouraging future clinical trials.
IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.
Equillium announced plans to initiate a pivotal study of itolizumab for acute graft-versus-host disease (GVHD) after positive topline data from the EQUATE study. Interim safety data from asthma patients in the Phase 1b EQUIP study was also reported. Financially, R&D expenses increased to $7.0 million, with a net loss of $10.3 million for Q3 2021. Equillium maintains a cash balance of $90.7 million, projected to fund operations into 2023. Guidance for topline EQUIP data is set for Q4, with pivotal study commencement expected early 2022.
Equillium (Nasdaq: EQ) is set to participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT and the Jefferies Virtual London Healthcare Conference on November 18, 2021, at 12:00 AM PT. The presentations will cover the mechanism of action of itolizumab, aimed at treating severe autoimmune disorders. Leadership will conduct one-on-one meetings at both conferences. Webcast access is available on the company’s website, along with archive replays for 90 days.
Equillium, Inc. (NASDAQ: EQ) announced interim results from its Phase 1b EQUIP study evaluating itolizumab in patients with moderate to severe uncontrolled asthma. The study demonstrated that itolizumab was well tolerated, with a reduction in asthma control questionnaire scores from 2.5 to 1.5 at Day 29. The mean FEV-1 improved from 2.1 to 2.4 by Day 29, maintaining this improvement at Day 85. Adverse events were mainly mild to moderate. Topline data is expected later this year, highlighting itolizumab's potential in treating severe asthma.
Equillium (NASDAQ: EQ) released positive interim data from the Phase 1b EQUALISE study of its drug itolizumab for patients with systemic lupus erythematosus (SLE). Results showed up to a 53% decrease in proteinuria, indicating potential kidney protection. The treatment was well tolerated, with mild to moderate side effects reported. Pharmacodynamic data revealed dose-dependent reductions in the inflammatory marker CD6. These findings support the drug's mechanism targeting the CD6-ALCAM pathway and highlight the ongoing research into its efficacy for SLE and lupus nephritis.